Zoetis Inc. (NYSE:ZTS) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other brokerages have also weighed in on ZTS. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a report on Tuesday, September 26th. Deutsche Bank AG restated a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Hilliard Lyons began coverage on shares of Zoetis in a report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 price objective on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a report on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the stock. Zoetis presently has an average rating of “Buy” and an average price target of $65.44.

Zoetis (ZTS) opened at 63.75 on Friday. The company has a market cap of $31.18 billion, a P/E ratio of 36.04 and a beta of 1.02. Zoetis has a 52 week low of $46.86 and a 52 week high of $65.83. The company has a 50-day moving average of $63.41 and a 200-day moving average of $60.49.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.49 EPS. On average, equities research analysts predict that Zoetis will post $2.34 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/bidaskclub-downgrades-zoetis-inc-zts-to-sell/1616495.html.

A number of institutional investors have recently modified their holdings of ZTS. CGOV Asset Management grew its position in Zoetis by 2.7% during the 1st quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock worth $12,059,000 after purchasing an additional 4,405 shares during the last quarter. Victory Capital Management Inc. grew its position in Zoetis by 738.5% during the 1st quarter. Victory Capital Management Inc. now owns 243,747 shares of the company’s stock worth $13,008,000 after purchasing an additional 214,676 shares during the last quarter. Blair William & Co. IL grew its position in Zoetis by 10.6% during the 1st quarter. Blair William & Co. IL now owns 2,430,593 shares of the company’s stock worth $129,695,000 after purchasing an additional 232,630 shares during the last quarter. William Blair Investment Management LLC grew its position in Zoetis by 3.7% during the 1st quarter. William Blair Investment Management LLC now owns 4,823,746 shares of the company’s stock worth $257,443,000 after purchasing an additional 173,898 shares during the last quarter. Finally, Cibc World Markets Corp grew its position in Zoetis by 51.7% during the 1st quarter. Cibc World Markets Corp now owns 51,383 shares of the company’s stock worth $2,742,000 after purchasing an additional 17,512 shares during the last quarter. 93.20% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.